Key result
Inhibiting four transcription factors drives cardiomyocyte proliferation and restores cardiac function in preclinical models.
Why the study?
Heart failure is characterized by dysregulated energetics and cardiomyocyte loss, creating an unmet need for effective regenerative therapies to overcome the limited regenerative capacity of adult cardiomyocytes.
Does combinatorial inhibition of E2F6, RARA, TCF7L2, and LEF1 (ERTL) promote cardiomyocyte proliferation and regeneration in preclinical models of heart failure?
Population
Post-mitotic rat cardiomyocytes, matured hiPSC-derived cardiomyocytes in vitro, and mice in vivo
Comparison
Combinatorial inhibition of E2F6, RARA, TCF7L2, and LEF1 (ERTL)
Design
Preclinical in vitro and in vivo study
Authors
Loading...
Hypothesis-generating for ERTL inhibition in cardiac regeneration; leaves open translation to human heart failure therapy.
Does combinatorial inhibition of E2F6, RARA, TCF7L2, and LEF1 (ERTL) promote cardiomyocyte proliferation and regeneration in preclinical models of heart failure?
Combinatorial inhibition of the transcription factors E2F6, RARA, TCF7L2, and LEF1 (ERTL) promotes cardiomyocyte proliferation and regeneration, offering a potential novel therapeutic strategy for heart failure.
Zhu et al. (2025) studied Heart failure. Combinatorial inhibition of E2F6, RARA, TCF7L2 and LEF1 (ERTL) was evaluated on Cardiomyocyte proliferation and contractile function. Combinatorial inhibition of four transcriptional regulators (E2F6, RARA, TCF7L2, and LEF1) drives cardiomyocyte proliferation and contractile function in vitro and in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: